Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19478676 | 0.90 | KDM4E (0.36) | KDM4EALDH1A1MEN1KMT2AMLYCD | |
| SCHEMBL17401062 | 0.90 | KDM4E (0.36) | KDM4EALDH1A1MEN1KMT2AMLYCD | |
| SCHEMBL16086532 | 0.89 | TSHR (0.44) | KDM4EALDH1A1MEN1KMT2AMLYCD | |
| SCHEMBL25493115 | 0.89 | KDM4E (0.41) | KDM4EALDH1A1MEN1KMT2ALTA4H | |
| SCHEMBL3485766 | 0.88 | EPHX2 (0.40) | MEN1KMT2AMLYCDDGAT1TSHR | |
| SCHEMBL46884 | 0.86 | KDM4E (0.39) | KDM4EALDH1A1MEN1KMT2AMLYCD | |
| SCHEMBL3705028 | 0.84 | MAOA (0.34) | MEN1KMT2AMLYCDLTA4HDGAT1 | |
| SCHEMBL7282196 | 0.83 | ALDH1A1 (0.42) | KDM4EALDH1A1MEN1KMT2ADGAT1 | |
| SCHEMBL1398380 | 0.82 | TSHR (0.52) | KDM4EALDH1A1MEN1KMT2ALTA4H | |
| SCHEMBL948359 | 0.81 | PAOX (0.38) | ALDH1A1MEN1KMT2AMLYCDDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836157-A | Oxadiazole derivative and preparation method and application thereof | 星希尔生物科技(上海)有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023179366-A1 | OXADIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 星希尔生物科技(上海)有限公司 | 2023-09-28 | — | — | WO | disclosed |
| US-8921576-B2 | Spiroindoline compound, and medicinal agent comprising same | KOWA COMPANY, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| EP-2781521-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-7781443-B2 | cholesteryl ester transfer protein (CETP) anatgonists such as 2R,4S)-4-{[3,5-Bis(trifluoromethyl)benzyl]-[5-(morpholin-4-yl)pyrimidin-2-yl]}amino-2-ethyl-6-methoxy-3,4-dihydro-2H-[1,5]naphthyridine-1-carboxylic acid ethyl ester, having improved bioavailability | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-24 | — | — | US | disclosed |
| EP-2139892-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| CN-100441579-C | Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors | TANABE SEIYAKU CO (JP) | 2008-12-10 | — | — | CN | disclosed |
| WO-2008119734-A2 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119734-A2 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008113711-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
| CN-1938301-A | Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors | TANABE SEIYAKU CO (JP) | 2007-03-28 | — | — | CN | disclosed |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | TANABE SEIYAKU CO., LTD. | 2007-02-08 | — | — | US | disclosed |
| EP-1732924-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095395-A2 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | KDM4E 1150/4885ALDH1A1 1365/4885MEN1 1136/4885 |
| US-20070032485-A1 | Tetrahydronaphthyridine derivatives and a process for preparing the same | CETP, MTTP, NPC1L1 | KDM4E 2158/4885ALDH1A1 3511/4885MEN1 3043/4885 |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | GCKR, GCK, GALK1 | KDM4E 4071/4885ALDH1A1 575/4885MEN1 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.